Global Systemic Lupus Erythematosus (SLE) Drugs Market to 2027 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 15, 2020--
The “Systemic Lupus Erythematosus (Sle) Drugs - Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering.
Global Systemic Lupus Erythematosus (Sle) Drugs Market to Reach US$264.5 Million by the Year 2027
Amid the COVID-19 crisis, the global market for Systemic Lupus Erythematosus (Sle) Drugs estimated at US$183.3 Million in the year 2020, is projected to reach a revised size of US$264.5 Million by 2027, growing at a CAGR of 5.4% over the period 2020-2027.
The U. S. Accounts for Over 29.5% of Global Market Size in 2020, While China is Forecast to Grow at a 5% CAGR for the Period of 2020-2027
The Systemic Lupus Erythematosus (Sle) Drugs market in the U. S. is estimated at US$54 Million in the year 2020. The country currently accounts for a 29.48% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$46.6 Million in the year 2027 trailing a CAGR of 5% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.1% and 4.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR while Rest of European market (as defined in the study) will reach US$46.6 Million by the year 2027.
The report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Competitors identified in this market include, among others:
- Amgen, Inc.
- Bristol-Myers Squibb Company
- GlaxoSmithKline PLC
- Immunomedics, Inc.
- Johnson & Johnson
- MedImmune LLC
- Merck Serono GmbH
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.
- UCB SA
Key Topics Covered:
I. INTRODUCTION, METHODOLOGY & REPORT SCOPE
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- Impact of Covid-19 and a Looming Global Recession
- Global Competitor Market Shares
- Systemic Lupus Erythematosus (Sle) Drugs Competitor Market Share Scenario Worldwide (in %): 2018E
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
- World Current & Future Analysis for Systemic Lupus Erythematosus (Sle) Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through 2027
- World Historic Review for Systemic Lupus Erythematosus (Sle) Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2017
- World 15-Year Perspective for Systemic Lupus Erythematosus (Sle) Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2018 & 2027
III. MARKET ANALYSIS
GEOGRAPHIC MARKET ANALYSIS
- Total Companies Profiled: 41
For more information about this report visit https://www.researchandmarkets.com/r/wbz6dt
View source version on businesswire.com:https://www.businesswire.com/news/home/20201215005625/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2020.
PUB: 12/15/2020 07:44 AM/DISC: 12/15/2020 07:44 AM